PEAK6 Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q2
$24.5M Sell
71,100
-4,300
-6% -$1.34M 0.1% 175
2018
Q1
$26M Sell
75,400
-98,200
-57% -$34.2M 0.11% 167
2017
Q4
$65.3M Buy
173,600
+19,600
+13% +$7.94M 0.3% 43
2017
Q3
$68.9M Buy
154,000
+3,200
+2% +$1.52M 0.35% 36
2017
Q2
$74.1M Buy
150,800
+94,000
+165% +$41.1M 0.43% 26
2017
Q1
$22M Buy
56,800
+18,600
+49% +$6.89M 0.18% 105
2016
Q4
$14M Hold
38,200
0.1% 230
2016
Q3
$15.4M Sell
38,200
-16,800
-31% -$6.74M 0.11% 196
2016
Q2
$19.2M Buy
55,000
+22,700
+70% +$8.74M 0.15% 132
2016
Q1
$11.6M Sell
32,300
-14,000
-30% -$5.77M 0.09% 266
2015
Q4
$25.1M Sell
46,300
-56,500
-55% -$30.6M 0.17% 104
2015
Q3
$47.8M Buy
102,800
+6,000
+6% +$3.22M 0.25% 45
2015
Q2
$49.4M Sell
96,800
-43,300
-31% -$21.1M 0.29% 32
2015
Q1
$63.3M Buy
140,100
+40,700
+41% +$17.2M 0.48% 8
2014
Q4
$40.8M Buy
99,400
+40,900
+70% +$16.1M 0.31% 23
2014
Q3
$21.1M Sell
58,500
-34,100
-37% -$11.4M 0.16% 116
2014
Q2
$26.2M Sell
92,600
-23,800
-20% -$7.05M 0.25% 51
2014
Q1
$35M Buy
116,400
+47,400
+69% +$14.6M 0.3% 26
2013
Q4
$19M Sell
69,000
-82,800
-55% -$23.8M 0.13% 124
2013
Q3
$23.8M Buy
151,800
+122,200
+413% +$32.1M 0.16% 72
2013
Q2
$6.66K Buy
+29,600
New +$6.89M 0.03% 545

Other funds holding REGN

PEAK6 Group's REGN Position: Q2 2018 in Review

PEAK6 Group sold out of Regeneron Pharmaceuticals (REGN) in Q2 2018, closing a stake of 4,713 shares — an estimated $1.47M sold.

PEAK6 Group first reported a position in REGN in Q3 2013 and held it in 13 quarters. The position peaked at $27.6M in Q3 2015. 624 funds tracked by Wall St. Rank hold REGN as of Q2 2018.

  • PEAK6 Group reported no remaining Regeneron Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • PEAK6 Group sold 4,713 Regeneron Pharmaceuticals shares in Q2 2018, an estimated $1.47M.
  • PEAK6 Group first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 13 quarters.
  • PEAK6 Group's Regeneron Pharmaceuticals position peaked at $27.6M in Q3 2015.
  • 624 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.